Drug sales in line with full year objective of 7.0% to 9.0% growth
- First half 2009 drug sales up 6.3% year-on-year at constant currency
- Dynamic Specialty care franchise: 11.5% sales growth at constant currency
Sustained profitability
- First semester impacted by the full consolidation of US acquisitions
- Group operating income1 reaches 25.0% of sales
Strong cash flow generation
- €147 million generated from operating activities during the first half 2009
- €119 million positive net cash position as of June 30, 2009
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group’s results for the first half 2009, published today. The full 2009 half year financial report is available on the Group’s web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.